The quarter materially exceeded the financial bar. Published expectations were roughly $23.6 million of revenue and a $0.43–$0.44 adjusted loss per share; Verastem delivered $40.1 million of total revenue and a $0.31 non-GAAP loss per share. The revenue beat was driven partly by a $15.0 million COPIKTRA milestone, so it is not purely evidence of recurring commercial strength.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Net product revenue | $25.1M | $2.1M (Income Statement) |
| COPIKTRA license and related-assets revenue | $15.0M | — (Income Statement) |
| Total revenue | $40.1M | ~$23.6M published consensus |
| Non-GAAP adjusted net loss per share | $(0.31) | $(0.62) (GAAP to non-GAAP Reconciliation) |
| Cash, cash equivalents and investments | $136.4M | $205.0M at Dec. 31, 2025 (Balance Sheet) |
| Pro forma cash | $201.4M | Includes expected $50.0M Oberland financing and $15.0M COPIKTRA milestone (Liquidity and Capital Resources) |
Commercial traction was better than the headline milestone alone suggests. Product revenue reached $25.1 million, up sharply from $2.1 million a year earlier, reflecting a full period of AVMAPKI FAKZYNJA CO-PACK sales and continued new-patient starts and refills (Income Statement; Business Update). That is the more durable positive in the quarter, although the filing does not provide enough detail to determine how much of the result was above the market's underlying product-sales expectation.
The funding update reduces near-term financing pressure, but the runway is conditional. Pro forma cash rises to $201.4 million after the expected August 28, 2026 Oberland closing and the $15.0 million milestone, with management projecting funding into the second half of 2027 (Liquidity and Capital Resources). The actual quarter-end cash balance fell by about $68.6 million from December 31, 2025, while operating expenses increased to $72.8 million from $45.9 million, including a 67% increase in R&D spending (Balance Sheet; Income Statement). The improved runway therefore depends on financing closing, milestone cash being received, future product revenue, and access to another Oberland tranche.
The pipeline update is encouraging but not yet a new expectation-reset. VS-7375 showed dose-dependent activity, target-supportive pharmacokinetics, and manageable tolerability across several KRAS G12D-driven cancers, with three registration-directed Phase 2 trials enrolling and additional data expected in October (Business Update — VS-7375). Because the filing describes early clinical activity rather than registrational efficacy, the update strengthens the story but does not yet establish a commercial or regulatory outcome.
Net: clearly better than the quarter's published financial expectations, with the biggest upgrade in liquidity and near-term commercialization. The quality of the beat is mixed underneath the surface because $15.0 million came from a milestone and the cash plan relies on a financing that had not yet closed as of June 30, 2026. Still, stronger recurring product revenue, lower adjusted loss per share, and the prospect of runway into the second half of 2027 make this a significant positive versus the standing expectation.
Read the original 8-K on SEC EDGAR ↗